Atopic Dermatitis - The Dermatology Digest

Phase 3 Data: Upadacitinib Shows Long-term Safety and Efficacy in Adolescents With AD

November 5, 2024

FDA Pushes PDUFA Date Back for Tapinarof Cream, 1% (Vtama) in AD; No Safety or Efficacy Concerns Cited

November 5, 2024

Done Deal: Organon Completes Acquisition of Dermavant

October 28, 2024

Unpacking LEVEL UP Period 2 Data With Dr. Christopher Bunick: Patients Who Switched From Dupilumab to Upadacitinib Hit Higher AD Treatment Targets

October 26, 2024

Fall Clinical News: Tapinarof Cream, 1% Maintains High Rate of Complete Clearance in Adults and Kids With AD

October 25, 2024

AD Pipeline Watch: Apogee’s APG777 Continues to Shine in Phase 1 AD Study

October 24, 2024

Advertisement

Latest Issue

Latest Supplements

Advertisement

Digital Edition Archive

Advertisement